Qian Feng, Bolen Christopher R, Jing Chunxia, Wang Xiaomei, Zheng Wei, Zhao Hongyu, Fikrig Erol, Bruce R Douglas, Kleinstein Steven H, Montgomery Ruth R
Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Clin Vaccine Immunol. 2013 Feb;20(2):146-55. doi: 10.1128/CVI.00530-12. Epub 2012 Dec 5.
Hepatitis C virus (HCV) is the most common chronic blood-borne infection in the United States, with the majority of patients becoming chronically infected and a subset (20%) progressing to cirrhosis and hepatocellular carcinoma. Individual variations in immune responses may help define successful resistance to infection with HCV. We have compared the immune response in primary macrophages from patients who have spontaneously cleared HCV (viral load negative [VL-], n = 37) to that of primary macrophages from HCV genotype 1 chronically infected (VL+) subjects (n = 32) and found that macrophages from VL- subjects have an elevated baseline expression of Toll-like receptor 3 (TLR3). Macrophages from HCV patients were stimulated ex vivo through the TLR3 pathway and assessed using gene expression arrays and pathway analysis. We found elevated TLR3 response genes and pathway activity from VL- subjects. Furthermore, macrophages from VL- subjects showed higher production of beta interferon (IFN-β) and related IFN response genes by quantitative PCR (Q-PCR) and increased phosphorylation of STAT-1 by immunoblotting. Analysis of polymorphisms in TLR3 revealed a significant association of intronic TLR3 polymorphism (rs13126816) with the clearance of HCV and the expression of TLR3. Of note, peripheral blood mononuclear cells (PBMCs) from the same donors showed opposite changes in gene expression, suggesting ongoing inflammatory responses in PBMCs from VL+ HCV patients. Our results suggest that an elevated innate immune response enhances HCV clearance mechanisms and may offer a potential therapeutic approach to increase viral clearance.
丙型肝炎病毒(HCV)是美国最常见的慢性血源性感染病毒,大多数患者会慢性感染,一部分患者(20%)会发展为肝硬化和肝细胞癌。免疫反应的个体差异可能有助于确定对HCV感染的成功抵抗。我们比较了自发清除HCV患者(病毒载量阴性[VL-],n = 37)的原代巨噬细胞与HCV基因1型慢性感染(VL+)受试者(n = 32)的原代巨噬细胞的免疫反应,发现VL-受试者的巨噬细胞Toll样受体3(TLR3)的基线表达升高。通过TLR3途径对HCV患者的巨噬细胞进行体外刺激,并使用基因表达阵列和通路分析进行评估。我们发现VL-受试者的TLR3反应基因和通路活性升高。此外,通过定量PCR(Q-PCR)发现VL-受试者的巨噬细胞产生更高水平的β干扰素(IFN-β)和相关的IFN反应基因,通过免疫印迹发现STAT-1的磷酸化增加。对TLR3多态性的分析显示,内含子TLR3多态性(rs13126816)与HCV清除和TLR3表达存在显著关联。值得注意的是,来自相同供体的外周血单核细胞(PBMC)显示出相反的基因表达变化,这表明VL+ HCV患者的PBMC中存在持续的炎症反应。我们的结果表明,先天免疫反应增强可促进HCV清除机制,可能为提高病毒清除率提供一种潜在的治疗方法。